Search

Displaying results 5911 - 5920 of 10000 in total
  1. Drug

    AS1409

    go.drugbank.com/drugs/DB05182
    Investigational

    It is developed by Antisoma is in a phase I of clinical trial for the treatment of renal cancer and melanoma. … AS1409 is a genetically engineered fusion protein made up of two distinct components. One is the cytokine IL12, which has anti-cancer activity. The other is an antibody that targets tumours.

  2. Drug

    Ciglitazone

    go.drugbank.com/drugs/DB09201
    Experimental

    Ciglitazone is a potent and selective PPARγ ligand with an EC50 of 3.0 µM. It is also an anti-hyperglycemic agent in the ob/ob murine model in vivo. … Ciglitazone was never used as a medication, but it sparked interest in the effects of thiazolidinediones.

  3. Drug

    POT-4

    go.drugbank.com/drugs/DB06056
    Investigational

    POT-4 is a peptide that specifically inhibits complement activation and is initially being developed for the treatment of age-related macular degeneration (AMD). … The investigational drug was under investigation in clinical trial NCT00473928 (Safety of Intravitreal POT-4 Therapy for Patients With Neovascular Age-Related Macular Degeneration (AMD) (ASaP)).

  4. Drug

    RAPA-501-Allo

    go.drugbank.com/drugs/DB15890
    Investigational

    RAPA-501-ALLO is composed of T-cells extracted from healthy volunteers; these cells are then reprogrammed _ex vivo_ in a process that involves de-differentiation and re-differentiation.[L16483]

  5. Drug

    AG0301-COVID19

    go.drugbank.com/drugs/DB15856
    Investigational

    On September 8, 2020 AnGes announced collaboration with Brickell Biotech, Inc. following completion of Phase 1/2 clinical studies (NCT04463472). … The gene transfer method increases the efficiency of gene expression and antibody production capability, garnering a more efficient DNA vaccine product.

  6. Drug

    Lufotrelvir

    go.drugbank.com/drugs/DB16514
    Investigational

    on preprint servers[L31733, L31125]. … Phase 1b studies are also exploring the safety and tolerability of PF-07304814 in COVID-19 patients who are hospitalized (NCT04535167).

  7. Drug

    Oxaprozin

    go.drugbank.com/drugs/DB00991
    Approved

    Oxaprozin is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis.

    Products: DURAPROX 600 MG FILM TABLET, 20 ADET
  8. Drug

    PRGN-3006

    go.drugbank.com/drugs/DB17229
    Investigational

    PRGN-3006 are autologous CD3+ T cells genetically modified using a non-viral system to express a CD33 CAR, membrane-bound interleukin-15, and a truncated form of human HER1T (kill switch) on the cell surface

    Synonyms: Autologous CD3+ T cells genetically modified using a non-viral system to express a CD33 CAR, membrane bound Interleukin-15, and a truncated form of human HER1t (kill switch) on the cell surface
  9. Drug

    NBF-006

    go.drugbank.com/drugs/DB21770
    Investigational

    NBF-006 is under investigation in clinical trial NCT03819387 (A Study of NBF-006 in Non-small Cell Lung, Pancreatic, or Colorectal Cancer).

  10. Drug

    Sirna-027

    go.drugbank.com/drugs/DB05896
    Investigational

    VEGFR-1 is a key component of the clinically validated vascular endothelial growth factor (VEGF) pathway. Sirna-027 is developed by Sirna Therapeutics and is under the phase I of clinical trails.